• In the past quarter, healthcare-focused fund VR Adviser, LLC disclosed selling 5,845,915 Ocular Therapeutix shares for an estimated US$70.96 million, reducing the position to a smaller slice of its reported assets.
• This fund rebalancing comes as Ocular Therapeutix faces softer quarterly results, declining revenue, and worsening adjusted operating margins, intensifying scrutiny of its operating model.
• Next, we’ll examine how these weaker quarterly results and margin pressures may affect Ocular Therapeutix’s earlier investment narrative built around AXPAXLI’s potential.

Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

Ocular Therapeutix Investment Narrative Recap

To own Ocular Therapeutix today, you need to believe that AXPAXLI can clear its Phase 3 hurdles and eventually translate into a meaningful retinal franchise, despite current losses and a narrow pipeline. The recent VR Adviser sell-down and weaker results highlight execution and funding pressures, but they do not directly change the near term clinical catalyst: topline SOL-1 Phase 3 data for AXPAXLI and the associated regulatory path. The biggest immediate risk remains any clinical or regulatory disappointment in these trials.

The most relevant recent announcement here is the February 2026 earnings release, which showed full year 2025 revenue falling to US$51.95 million and the net loss widening to US$265.94 million. Against that backdrop, the VR Adviser reduction and margin pressure draw more attention to whether AXPAXLI and the broader hydrogel platform can eventually offset ongoing cash burn and dilution concerns as the SOL program and HELIOS-3 move forward.

Yet behind AXPAXLI’s promise, investors should be aware that sustained high cash burn and potential future dilution could...

Ocular Therapeutix's narrative projects $192.9 million revenue and $44.8 million earnings by 2028.

Uncover how Ocular Therapeutix's forecasts yield a $24.17 fair value, a 192% upside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were modeling revenue near US$252 million and earnings of about US$58 million by 2028, which is far more upbeat than the dilution and profitability concerns many investors are now focused on, so it is worth remembering that views on Ocular’s risk reward profile can differ sharply and may shift again as the latest results and VR Adviser exit are fully digested.

Explore 6 other fair value estimates on Ocular Therapeutix - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.